Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality.
Each year of delayed amyloidosis diagnosis increases heart failure mortality risk by 7%, establishing urgency for faster recognition.
In 7,770 Medicare and 2,557 VHA patients with ATTR-CM, median time from heart failure diagnosis to amyloidosis diagnosis was ~490 days, and each year of diagnostic delay independently increased the risk of death or HF hospitalization by 7% after adjustment for sociodemographics and comorbidities in both cohorts. These findings across two large real-world populations establish diagnostic delay as a clinically meaningful and quantifiable prognostic marker in ATTR-CM, where disease-modifying therapy (tafamidis) is now available.
What the study was
- Study design
- retrospective cohort
- Population
- Medicare and VHA patients with transthyretin cardiac amyloidosis
- Sample size
- 10327
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- JACC Advances
Why it surfaced
Quantifies the mortality and morbidity burden of diagnostic delay in ATTR-CM with large two-cohort real-world evidence; provides the evidence base for earlier ATTR-CM screening initiatives and reinforces urgency of earlier tafamidis initiation given the 7% per year risk increment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.